1.National Cancer Institute SEER (1973-1995). Brain and other nervous system cancer. Trends in SEER incidence and U.S mortality. Cancer Statistics Review. 2.Cancer Statistics 2004. The American Cancer Society. 3.Mendoza, A y cols Resumen Incidencia de tumores Cerebrales primarios en adultosIV Congreso Virtual Hispanoamericano de Anatomía Patológica 1-31 marzo 2004) 4.Grossman S, Fisher JD, Piantadosi S, and Brem H. The new approaches to brain tumors. Cancer Control: JMCC 1998; 107-114. 5.Giese A, Bjerkving R, Berens M.E, and Westphal M. Cost of Migration Gliomas and Implications for Treatment. J Clinical Oncology 2003; Vol 21, 1624-1636. 6.Stewart LA. Meta-Analisis Group MCTU: Chemotherapy in adult high-grade glioma: A systematic review and meta-analisis of individual patient data from 12 randomised trials. Lancet 2002, 359: 1011-1018 7.National Institute of Cancer. Adult Brain Tumor (PDQ). 2004. 8.Wersall P. et al. Intratumoral infusions of the monoclonal antibody, mAb 425, against the epidermal groth factor receptor in patients with advanced malignant gliomas. Cancer Immnunol. Immunother 1997; 44: 157-164. 9. AJCC. Cancer Staging Handbook. Six Edition. 10. Perry JR, Cairncross JG. Glioma Therapies: How to tell which work? Journal of Clinical Oncology 2003. Vol 21, 3547-3549. 11.FDA –AACR Brain Tumor Endpoints Workshop, Bethesda, MD Jan 20, 2000 12.Brada M. Radiotherapy in malignant glioma. Annals of Oncology 17 (Supplement 10): x183-x185, 2006. 13.M. J. van den Bent. Adjuvant treatment of high grade gliomas Ann Oncol 17: x186-x190, 2006. 14.. Mendelsohn J, Baselga J. Status of Epidermal Growth Factor Receptor Antagonist in the Biology and treatment of Cancer. Journal of Clinical Oncology 2003. Vol 21, 2787-2799. 15. Tremont-Lukats I.W, Gilbert M.R. Advances in Molecular Therapies in Patients with Brain Tumors. Cancer Control 2003. Vol 10, 125-137. 16.Yang L, Ka-yun Ng, Kevin O, Lillehei. Cell Mediated Inmmunotherapy: A new approach to the treatment of Malignant Glioma. Cancer Control 2003. Vol 10, 138-147. 17.FeldKamp MM, Lau N, Guha A. Signal transduction pathways and their relevance in human astrocytomas. Cancer Immunol Immunother 1997; 44 : 157-164 18. Libermann TA et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 1984; 4: 753-760. 19. Steck PA., Lee P., Hung MC., Yung WKA. Expression of an altered epidermal growth factor receptor by human glioblastoma cells. Cancer Res 1988; 48:5433-5439. 20.Van der Valk P, Lindeman J., Kamphorst W. Growth factors profiles of human gliomas. Do non-tumor cells contribute to tumor growth in glioma? Ann Oncol 1997; 8:1023-1029 21. Ragel B, Jensen R.L. New approaches for the treatment of refractory Meningiomas. Cancer Control 2003. Vol 10, 148-158. 22.Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal factor receptors, Ras-guanosine triphosphate, and mitogen activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999; 45 (6):1442-1453 23..Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets. 2002 Jun;2(2):91-10 24. .Khoshiomn S, et al. Inhibition of phospholipase C-gamma 1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates. Neurosurgery 1999; (44) 3: 568-577. 25.Laerum OD, Nygaar SJ, Steine S, Mork SJ, Engebraaten O, Peraud A, Kleihues P, Ohgaki H. Invasiveness in vitro and biological markers in human primary glioblastomas. J Neurooncol. 2001 Aug;54(1):1-8 26.Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998; 4(5):286-295. 27.Kerbel RS. Tumor angiogenesis: past, present and near future. Carcinogenesis 2000; 21 (3) 505-515.Cohen S. Human Epidermal growth Factor: Isolation and Chemical and Biological properties. Proc. Natl. Acad. Sci, USA. 1975; 72 1: 317. 28.Stocheck CM.: Role of the Epidermal Growth Factor in Carcinogénesis. Cancer Research. 1986; 46: 1030-1037. 29.Carpenter G. Cohen S. Epidermal Growth Factor. Annu Rev Biochem. 1979; 48:193-216. 30.Gregory. H, Isolation and structure of urogastrone and its relationships to Epidermal Growth Factor. Nature. 1975; 257: 325-327. 31.Gray A., Dull TJ., Ullrich A. Nucleotide sequence of Epidermal Growth Factor. Nature. 1983; 303:722-725. 32.Scott J, Urdea M., Quiroga M., Fong N., Rutter WJ. Structure of mouse submaxilary messenger RNA encoding EGF and 7 related proteins. Science. 1983; 221: 236-240. 33.Pérez R., Lage A., Los factores de crecimiento y sus relaciones con la transformación maligna. Interferón y Biotecnología 1994; 3(3): 179-2093 34.Greenfeld C., Hills H., Watterfield MD., Blundell TL . EGF binding induces a conformational change in the external domain of its receptor. Emb J 1989; 8:4115-412432.Ullrich. A, Schellinger J., Signal transduction by receptor with tyrosine kinase activity. Cell. 1990; 61: 203-212. 35.Liu KJ, Chen CT, Hu WS, Hung YM, Hsu CY, Chuang BF, Juang SH. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme. Int J Oncol. 2004 Mar;24(3):581-90 36.Schellinger J., Signal Transduction by allosteric receptor oligomerization. Trends Biochem. Science. 1990; 13: 443-447. 37.Merlino G.T, Xu Y. Ishu S. Application and enhanced expression of the EGF-R in A-431 carcinoma cells. Science. 1984.224:417-419. 38.Yamamoto T., Nishida T, Kawai S. The erb gene of avian erytoblastosis virus is a member of the src family. Cell.1983; 35:71-78. 39.Haley D., Hsuan JJ, and Watterfield. Analysis of the mammalian fibroblast transformation by normal and mutated human EGF receptors. Oncogene 4. 1989; 4:279-283. 40.Santon JB, Cronin MT, Mendelshon J. Effects of the EGFR concentration on tumorigenicity of A431 cells in nude mice. Cancer Research. 1986; 46:4701-4705. 41.Filmus T. Trent J.M., Pollack M. EGF R gene amplified MDA 468 breast cancer cell line and its nonamplified variants. Molecular and Cellular Biology, 1987; 7:251-256. 42.Pérez R, Pascual MR, Macías A and Lage A. EGF receptors in human breast cancer. Breast Can. Res.Treat., 1984; 4:189-193. 43.Ríos MA, Macías A, Pérez R and Lage A. Receptors for EGF and estrogen as predictors of relapse in patients with mammary carcinomas. Anticancer Res. 1988; 8:173-176 44.Uhlman D.L, Nguyen P., Manivel J. Clinical Cancer Research. 1995; 1:913-920. 45.Aaronson A.S, Growth Factors and Cancer. Science, 1991; 254: 1146-1152. 46.Putsztai L., Lewis C., Lorenzen J. Growth Factors: regulation of normal and neoplastic growth. J. Pathol 1993; 169: 191-201. 47.Margollis B., Rhee SG., Felder S., Mervic M. EGF induces tyrosine phosphorylation of Phospholipase CII: A potential mechanism for receptor signaling. Cell 1989; 57:1101-1107. 48.Gordon T., Carpenter Epidermal Growth Factor: The receptor and its function. Biofactors 1989; 2:11-15. 49.Countway JL., Mcquilkin P., Girones N., Davis RJ. Multisite phosphorilation of the Epidermal Growth Factor. J Biol Chem, 1988; 263:3610-3617 50.Osborne C.K., Arteaga CL. Autocrine and Paracrine Growth Factor regulation of breast cancer: Clinical implications. Breast Cancer Research Treatment 1990; 15: 3-11. 51.Pérez R., Pascual MR., Macías A. and Lage A.: Epidermal Growth Factor receptors in human breast cancer. Breast Cancer Res. Treat. 1984; 4, 189 193. 52.Kaplan. PL., Andersen M., Ozanne. B. Transforming Growth Factors enables cells to growth in the absence of serum: an autocrine system. Proc Natl Acad Sci USA 1982; 79, 485-489. 53.Pérez R., Betsholtz C., Westermark B. Frequent expression of growth factors for messenquimal cells in human mammary carcinoma cell lines. Cancer Research 1987; 47, 3425-3429. 54.Dobashi Y., Stren DF., Membrane anchored form of EGF stimulate focus formation and intercellular communication. Oncogene. 1991; 6:1151-1159. 55.Castellani R., Vischer DW., Wykes S., Sarkar FH. Interaction of transforming growth Factor alfa and EGF receptor. An immunohistologic study. Cancer. 1994; 73(2): 344-349. 56.Ramnarayan K., Skaletsky E.. Antibody humanization predicted by computer Graphic Analysis. Am. Biotechnology Lab. 13 (9): 26-28.; 1995 57.C. Mateo, E. Moreno, K. Amour, J, Lombardero, W. Harris and R. Perez. Humanization of a mouse monoclonal antibody that blocks the EGF-R: recovery of antagonistic activity. Immunotechnology 1997; 3: 71-81. 58.Crombet T., Torres O., Rodríguez V., Menéndez A., Stevenson A., Ramos M., Torres F., Figueredo R., Veitía I., Iznaga N , Pérez R and Lage A. Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor in advanced brain tumor patients. Preliminary study. Hybridoma, 2001; Vol 20, Number 2. 59.Burtness BA, Li Y, Flood W, et all. Phase III trial comparing cirplatin (C) + Placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head and neck cancer (HNC). Proc Am Soc Clin Oncol 2002. Vol 21, 901. 60.Tewes M, Schleucher N, Dirsch O, et all. Results of a phase I trial of a humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. Proc Am Soc Clin Oncol 2002. Vol 21, 378 61.Tewes M, Schleucher N, Dirsch O, et all. Results of a phase I trial of a humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. Proc Am Soc Clin Oncol 2002. Vol 21, 378 62.Burtness BA, Li Y, Flood W, et all. Phase III trial comparing cirplatin (C) + Placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head and neck cancer (HNC). Proc Am Soc Clin Oncol 2002. Vol 21, 901. 63.Miyamoto C. et al. Utilization of 125 Iodine monoclonal antibody in the management of primary glioblastoma multiforme. Radiat Oncology Investigation 1995; 3:126 64.Faillot T et al. A Phase I study of an anti-Epidermal Growth Factor Receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 1996; 39:478-483 65.Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Perez R, Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003 Mar-Apr;26(2):139-48. 66.Tania Crombet Ramos, Rolando Pérez Rodríguez, Agustín Lage Dávila, Marta Osorio Rodríguez, Teresa Cruz. Anticuerpo monoclonal humanizado h-R3:un nuevo concepto terapéutico para el tratamiento del cáncer avanzado Biotecnología Aplicada 2003; Vol.20, No.1 67.Tania Crombet Ramos et al. Treatment of High-Grade Glioma Patient with the Humanizad Anti-Epidermal Growth Factor Receptor (EGFR) Antibody hR3: Report from a Phase I/II Trial Cancer Biol Ther. 2006 Apr 19;5(4) 68.Declaración de Helsinki en la WMA General Assembly, Edimburgo, Escocia, Octubre, 2000. 69.Directrices sobre Buenas Prácticas Clínicas en Cuba. Ciudad Habana 2000 70.National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), versión 3.1, 2003 71. Un estudio multicéntrico, abierto y aleatorio para determinar la seguridad y eficacia del h-R3 en combinación con quimioterapia y radioterapia o radioterapia sola en pacientes con diagnostico histológico de Carcinoma avanzado (Estadio III o IV) de Células Escamosas de Cabeza y Cuello (CCECC) Biocon Biopharmaceuticals Private Limited20th KM Hosur Road Electronic City P.O. Bangalore 560 100 INDIA, 2004 72.MacDonald response Criteria Journal of clinical oncology Vol 8,No 7 (july),1990:pp 1277-1280 73.Salmon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus monolconal antibody against HER2 for metastasic breast cancer that overexpressed HER@. N Engl J Med, 344: 783- 792, 2001. 74.Informe parcial del estrato Glioblastoma Multiforme entregado al CECMED en septiembre 2008 75.Monika E. Hegi et al. MGMT gene Silencing and Benefit from Temozolomide in Glioblastoma.The New England Journal of Medicine 2005; 352; 10: 997-1002 76.Alba A Brandes et al. MGMT Promoter Status Can Predict the Incidente and Outcome of Pseudoprogression alter concomitant Radiochemotherapy in newly diagnosed Glioblastoma patients. Journal Clinical Oncology 2008; 26: 2192-2197
